Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Let's recall, that was April-June....right in the heart of the pandemic when most everything shut down. Plus, they didn't have the capital to close big purchase orders back then, now they do. The opportunity is in front of us, not behind.
No, you would not be subject to filing tax returns in Canada.
Initial price must be $4 and maintain $1.
Studies show reverse splits into an uplist don’t cause a decline, actually it's the opposite. You have to separate a reverse split from a reverse split to achieve an uplist - two very different impacts on share price.
I doubt it would come into play until north of $5. They have plenty of cash near term and making good progress. Technically it seems poised to make a move IMO and the fundamental progress and valuation would warrant it. Just one man's view.
Looks like the bus (electric bus of course) is starting to leave the station. Market cap still low with plenty of upside potential.
Yeah, some of the online guys you have to call it in and some you don't. It's a pain until it is listed on Nasdaq soon.
They are going to be cashed up for a while with non-dulitive capital coming to fund the continued build out. The dollar volume in the stock is enough to chew through it IMO. In the old days, I would have worried, but the money flowing in is massive. They digested that $3 raise in less than a week and went right back on trending up. That would have put them in the penalty box for six months a while back. I hear ya, but it's a different market out there.
GreenPower Motor could be another name in the space to watch, symbol GPVRF. All electric bus company uplisting soon. $10 mil in rev last six mo and break even adjusted ebitda. Only like a $37 mil mkt cap but trending higher w the group. WKHS trading like a beast!
I can't imagine it would be the company, probably one of the many debt holders they have independently trying to stir up some volume. That happened not long ago here, it is likely the same nonsense. Regardless, it never looks good.
FTE today enters its 2,276th waiver.....how ridiculous is this nonsense??? These guys can't even go belly up right. I'm still amazed the stock was trading well over a buck right before it was halted. I figured it would have been a quarter. Probably shorts from the high single digits covering because it seemed inevitable it would be halted one day soon and they would rather just buy it back and book their huge gains rather than squeeze last drops of blood out of it.
That is great news out today in the 8k! Lots of progress across the board at the company.
And I'm not oversimplifying the challenges they have ahead, it still has a ton of risk and needs a lot of work -- but I just think this valuation has been so skewed downward by toxic debt for so long that a potential snap back to a reasonable (even conservative) valuation would mean multiples of where the stock is trading today. High risk....but ultra high reward....that type of deal.
That's exactly what I was thinking, absent supply from toxic note conversions this should be an entirely different stock. It sounds like manufacturing is ramping back up this month too for the Aftermaster Pro and then the sound bar is not far behind that. I have an Aftermaster Pro and love it, that's why I am here. I think they are on to something with the technology. I think a sound bar is a much more mainstream way to get the technology out to the masses. The soundbar entering the market and zero supply of stock from convertible notes could be a great combo this summer.
That is some pretty big news today they filed in the 8k about the agreement to restrict toxic debt conversions going forward. That is exactly what this company needed. If it weren't for the debt, this thing would be in the $0.10-$0.15 range IMO. This one got a lot more interesting today.
I have tracked the name for a while and agree with you. That being said, I spoke with management at a recent conference and I liked some of the ideas they had regarding how to work with the debtholders to get out of it. It seems like just recently they are seeing increased activity at the front end of the sales funnel as well. I know this company had a couple false starts before, I know the history, but if I was a gambling man I would be taking a hard look right here....especially for those like me that actually have an Aftermaster Pro in their living room and believe in the technology.
Anybody out there tracking this one? The whole equation looks like it is finally starting to come together. They have some hair to shave off still, but I see some explosive potential if they play their cards right.
It is funny that the guy that is calling the company a scam is the one trying to perpetuate all these falsehoods. The two Alpine notes are collectively convertible into approximately 2.2 million shares and that number is fixed. That was based off the 525,000,000 shares outstanding at the time of issuance when they got 42%. THIS IS NOT A FLOATING NUMBER....it was set at that time and did not increase when the authorized went to 750 mil nor will it increase in the future. Admittedly, this language could be worded a bit better in their filings. If you don't believe me, email the company and ask them. In the future why don't you actually try to verify your interpretation of the documents prior to making such statements rather than try to scare people that may mistakenly think that you know what you are talking about.
Because that is what GREAT stocks do!!!
Because that's what GREAT stocks do!!!
How did you think they were going to raise the capital necessary to launch and grow that business? What did you think they would just click their heels and have the finance fairy bring them $6 million to roll it out? Strategic investments like this happen all the time in business - especially in oil and gas and drug development. This isn't unusual at all. It is a fantastic deal for the company. I think the stock will increasingly reflect that. This was the missing piece of the equation they needed, and they hit it out of the park with this deal. This director has much better insight on the potential of this program than any of us, and to write a monster check w no guarantee of royalties is a big vote of confidence in its potential.
Yes
It probably depends on how the NIDA grant is accounted for - and we will find out more when the K is filed in a day or two. With $6 mil in equity raised they probably are still a bit short of the $4 mil shareholder equity requirement. That is really the critical variable, if we can make that hurdle we can get uplisted. If not there we should be very close. I will circle back on this after K is filed.
Most importantly, this should pave our way to the Nasdaq listing. This raise was the last hurdle. We should be ringing the opening bell on Nasdaq within six weeks or so. That opens us up to a whole new audience. This deal was huge for the company in so many ways.
His post is riddled with uneducated statements. The fact the buyer is entitled to potential future royalties does not lower the price paid. It would simply lower future revenues associated with that product by what I would estimate is 3-5%, which is entirely in line with industry standards. That is a very small amount to pay given the premium paid over the market price. If you sold them the stock at $4, that would be 1.5 mil shares, not 400k. That is a difference of 1.1 mil shares and at the current $4, about $4.4 mil. So think about it, that means the product has to generate about $100 mil in revs for the investor to recoup that premium he paid. It is a HUGE vote of confidence in BICX by the investor.
You are going so far as to call a company a scam for only disclosing small royalties in the body of the press release and not in the headline? That is the dumbest statement I have heard and gives you zero credibility. You want them to lay out the terms of the royalty agreement in the headline??? Moronic!! For an OTCQB company to raise money at $15 when trading at $4, while also giving up what is likely to be a 3-5% royalty is a huge vote of confidence in the company and a major positive. I hear/read a lot of stupid things but this one really stands out.
This one is getting interesting. Mkt cap still low and seems like big names associated. Key is how fast they can get Backchannel to mkt. Anybody else watching?
I did. It was really solid and went into greater detail than I had seen before. I think there is a replay available if you want. I think once they get their capital raising figured out near term, you will see this thing come to life. Deep pocketed insty guys are behind it funded it out of bankruptcy last year, but if they got some new life sciences specific funds in an equity deal this thing has a lot of upside. Benz seems like a low risk development opportunity with a lot of reward potential given the PRV upside. That alone is worth multiples of the market cap and this is a drug that has been used by something like 10k people effectively in South America - they aren't reinventing the wheel here. They have solid assets, with a little capital in the right form, I love it.
Anybody else going to join that company webinar presentation too?
My bad, I misread your post. Disregard last.
Hey Swami, what makes you say he has any sort of control? Just curious.
$125 mil to $350 mil is recent range of prices paid for a priority review voucher - they are fully transferable....
Tell that to United Therapeutics (UTHR).....they sold theirs for $350 mil
You still own this one Shadow?
Write up on medium website by Dallas Salazar - getting some press these days.
Taking 10% of a $200 Million Market? Startup BioCorRx Thinks It’s Just a Start
A uniquely derisked biotech-startup is looking to leverage an alternative delivery method for an already FDA-approved base treatment
BioCorRx, while being a long, long way from its ultimate goal, has the structure and the team in place to compete for an initial goal of just 10% target-market share; which would have the biotech startup well on its way to realizing much grander ambitions
BioCorRx, Inc. (OTC: BICX)?—?an addiction treatment biotech offering the BioCorRx® Recovery Program [a nonaddictive, medication-assisted treatment (MAT) program for alcohol and opoid abuse]?—?has a unique business model and market capture strategy; and it’s one that you don’t often see or hear promoted in the biotech space. Admittedly, this isn’t a space that I spend much time in. For the most part that’s because of the binary outcomes that are often associated with early stage investing (or any stage really). Ironically, this reluctance to invest and the reasoning behind my reluctance is what made BioCorRx so interesting. I’ll explain.
All too often when looking for a biotech investment, investors find themselves in situations which are nearly impossible to risk manage; and again, this is just the nature of the biotech space. A drug/therapy/treatment/device is either going to work or it isn’t. It’s either going to be approved or it isn’t. It’s either going to get the right kind of exclusivity or it isn’t. All of these outcomes, usually, are binary.
The worst part of it all? Often these scenario outcomes are the direct result of the decision making of a constantly changing a panel of experts; human experts which introduce an element of human uncertainty based on human interpretation. How you do risk manage how risky or efficacious or life quality altering a panel of individuals decides something is? The answer: you can’t.
And that’s just the starting point. Even if you and your investment manage to sidestep the danger zone that is “coming to market”, from there you and your investment have to have the right marketing strategy, the right amount of funding to execute the right marketing strategy, the right marketing strategy and right amount of funding to hire the right sales team to execute the right marketing strategy, etc. (and so on and so on). Simply being approved, while this might have created an exit opportunity or two along the way for investors, isn’t the “end all be all” for the ultimate success of the underlying enterprise or the investment longer-term. There is still much, much risk on the back-end of approval.
But none of this is ever outlined for investors not “in the know”, myself generally included. Pitchbooks and/or management presentations are usually completely absent anything detailed above. That is, until I had the opportunity to sit in on a BioCorRx presentation. BioCorRx’s presentation didn’t just outline these risks?—?it outlined many more. Specifically, how none of these apply to it. And for me, this was a presentation worth writing home (or to Medium readers) about.
Taking 10%: How BioCorRx is Derisking Investment
First, BioCorRx’s treatment program (which it believes to be the most comprehensive in the space) consists of two main components. The program consists of an outpatient implant procedure performed by a licensed physician with the second component being a long-term counseling/recovery program. The implant delivers a non-addictive medicine; naltrexone, an opioid antagonist that can significantly reduce physical cravings for alcohol and opioids. Naltrexone essentially “fills” open dopamine receptor “slots”, preventing the “slots” from taking in dopamine engagement from obsessive addictions (drinking, drug use, gambling, etc.). Again, BioCorRx has a centered focus on treating opoid and alcohol abuse?—?two of the most prominent and damaging abuse classifications in the United States. Naltrexone was FDA approved in 1984, has a long track record of safety, and is non-narcotic and non-addictive.
BioCorRx holds worldwide rights (ex. Australia and New Zealand) to a proprietary naltrexone-based implant which lasts several months, alleviating the need for daily dosage (normally a hurdle to program compliance and a general program efficacy hurdle/variable). To be clear, BioCorRx’s proprietary, extended-duration naltrexone blend is NOT FDA approved BUT does NOT require FDA approval for deployment; in fact it is currently, has already been, and will continue to be in deployment. Over the last few years, hundreds of patients have received the implant. Currently, BioCorRx’s proprietary, extended-duration naltrexone blend is responsible for driving a meaningful amount of the startups revenues. That said, what really caught my attention when it came to BioCorRx wasn’t its implant, as impressive as it is, but its plan to develop a long-lasting injectable version of naltrexone.
After doing some background research and hearing repeated success stories from doctors deploying the BioCorRx implant on the front line, I realized the manner in which we treat addiction as a society is rapidly evolving; and that the underlying market being attacked by BioCorRx is ripe for disruption. To this end, BioCorRx (in something of a coup) recently retained Dr. David Gastfriend. Gastfriend was previously VP of Scientific Communications for $7 billion market cap, publicly traded Alkermes (NASDAQ: ALKS). Gastfriend was also heavily involved with Alkermes’ famed Vivitrol. Vivitrol is Alkermes’ own long-lasting naltrexone injection; which is FDA approved and currently doing $200 million in annual revenues. It deserves noting that Vivitrol’s revenues are projected to grow to $460-$475 million by 2021. Gastfriend was retained by BioCorRx to help provide leadership and expert insight into direction and execution of all things FDA related.
I think, and I’ve been advised, that Gastfriend guiding BioCorRx through this process significantly derisks the negative outcome scenarios (or rather increases the possibility of a positive outcome)regarding BioCorRx taking its proprietary, extended-duration naltrexone injection down the regulatory pathway. Again, we’re talking about a significant, human-element introduced risk (the FDA approval process); but we’re also talking about a gentlemen who has “been here before” and about an already approved drug (in naltrexone) BioCorRx is delivering via proprietary methods. While there is certainly always risk in drug development, BioCorRx is simply seeking FDA approval of a different delivery mechanism rather than creating a drug from scratch. This should do well to decrease net risk?—?and I like that a lot.
BioCorRx has developed a two component, comprehensive program which aims to treat the underlying treatment-triggering disease rather than simply prescribing masking or short-term solution agents
Taking 10%: Medication Assisted Treatment
While BioCorRx is working aggressively to further its drug development pipeline, it’s also working with partner clinics across the US (which utilize its proprietary naltrexone implant in combination with the BioCorRx Recovery Counseling Program). BioCorRx is unique in this regard, providing both the medicinal assistance for those suffering from addiction and the long-term counseling they need to heal both physically and mentally. BioCorRx’s naltrexone implant provides patients a window of time where they can be free of cravings while they receive the counseling to help address broader abuse issues.
BioCorRx views the healing process as a minimum year long endeavor, but unlike the vast majority of other programs there is minimal disruption to daily life throughout the treatment process. The actual implant procedure is a simple 20 minute procedure using local anesthesia. Patients return to work the next day and have zero associated maintenance for several months. Counseling can be done either in person or virtually, offering complete confidentiality. BioCorRx seems to be in the right spot at the right time?—?doing all the right things.
All of the above in mind though, this isn’t really what you should be excited about. What you should be excited about is what BioCorRx management and Board of Directors have been able to do to position the startup for success; Gastfriend engagement inclusive. I don’t think Gastfriend comes to a biotech-startup without investigating first; the guy isn’t going to be associated with a subpar product (READ: the underlying startup) or claims without merit. So, that matters to me in “reading between the lines”. Stay tuned for updates here.
Taking 10%: Derisking/Reward
In a regulatory environment shifting further and further into one that prefers a treatment program focus on actually treating rather than masking or blocking, BioCorRx is well positioned to execute on an initially conservative goal
Our job as investors is to find asymmetric risk/reward opportunities. I think BioCorRx could be a unique opportunity to gain exposure to the type of upside that Alkermes has found with Vivitrol; which has been massive. I also think that despite having such attractive upside, the BioCorRx story offers limited, reward-weighting risk. In other words, I think the risk/reward at BioCorRx is in fact asymmetric.
I think that at some point, post-FDA approval (should BioCorRx ever achieve this), because of some of the inconveniences of Alkermes’ own naltrexone product (it’s an injection that’s quite painful, it’s an injection that requires a large needle to administer, it only lasts 30 days per injection, delivery can be uneven, etc.) that it makes some amount of sense (recovery program value-add inclusive) for Alkermes to consider simply taking out BioCorRx to acquire its technology, infrastructure, talent, product pipeline (at that point), etc. Monetization of the entire company at BioCorRx isn’t that hard to imagine, even though I don’t think investors should in any way price this in. Still, it’s worth mentioning.
You should also know that BioCorRx was on the verge of being taken private at one point by the same VC fund that decided to invest $2.5 million earlier this year in the current public format. The market hasn’t valued the startup with anything resembling a speculative multiple?—?and that should matter to investors looking to invest at the current rounds. Yes, even given the unusually derisked story here BioCorRx today only commands a $12 million market cap and at June 30, 2016 BioCorRx reported having $1.4 million in cash on its balance sheet.
I’ve been impressed in chatting with BioCorRx management and in chatting with its consulting teams. I’m also impressed in the investment thesis that exists even at just a 10% market take. Given the setup, I don’t think that’s too far fetched a goal. I can also really appreciate the conservatism in laying out a base investment thesis by those involved in the story.
For now, I’m watching closely from the sidelines. BioCorRx expects the first animal testing data on its long-lasting injectable in development later this year or early next. BioCorRx might be on to something big. I think this one might have the startup upside that so many of us operating in the space look for. Stay tuned.
Addiction RecoveryAddiction TreatmentAlcohol AddictionStartupVenture Capital
My understanding is concurrent paths. I think the injectable has the grand slam potential, but they will continue to push the implant forward as well. I think they look at it as providing multiple menu item for doctors to choose from, some circumstances may warrant one over the other and they want to be able to offer both. I talked to a guy who attended a recent addiction treatment conference and he said by all indications there was intense interest in what BICX is doing. They seem to be in the right spot at the right time for sure.
My understanding is concurrent paths. I think the injectable has the grand slam potential, but they will continue to push the implant forward as well. I think they look at it as providing multiple menu item for doctors to choose from, some circumstances may warrant one over the other and they want to be able to offer both. I talked to a guy who attended a recent addiction treatment conference and he said by all indications there was intense interest in what BICX is doing. They seem to be in the right spot at the right time for sure.
Where did the chart come from of vivitrol unit volumes? Great information. Thx for sharing.
Great looking graph, who made that quote? Interesting.
Big buyer was out there earlier trying to pick up a chunk....70,000 shares or so.